Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 7Unknown 2Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 78Leukemia, Lymphocytic, Chronic, B-Cell 77Leukemia 77Myelodysplastic Syndromes 61Lymphoma 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Multiple Myeloma 46Lymphoma, Non-Hodgkin 45Hodgkin Disease 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Hematologic Neoplasms 27Melanoma 26Recurrence 20Lymphoma, Follicular 18Lymphoma, Mantle-Cell 17Myeloproliferative Disorders 16Graft vs Host Disease 15Primary Myelofibrosis 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell 13Neoplasms, Plasma Cell 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myelomonocytic, Chronic 10Anemia, Aplastic 10Neoplasms 9Hematologic Diseases 9Neoplasm Metastasis 8Blast Crisis 8Anemia, Refractory, with Excess of Blasts 8Ovarian Neoplasms 7

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioblastoma × fludarabine × Clear all
NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡